These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Yang SY Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693 [TBL] [Abstract][Full Text] [Related]
4. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy. Maurer T Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602 [TBL] [Abstract][Full Text] [Related]
5. NMR in drug discovery on membrane proteins. Wirmer-Bartoschek J; Bartoschek S Future Med Chem; 2012 May; 4(7):869-75. PubMed ID: 22571612 [TBL] [Abstract][Full Text] [Related]
6. Application of NMR screening in drug discovery. Fejzo J; Lepre C; Xie X Curr Top Med Chem; 2003; 3(1):81-97. PubMed ID: 12570779 [TBL] [Abstract][Full Text] [Related]
7. NMR in drug discovery. Pellecchia M; Sem DS; Wüthrich K Nat Rev Drug Discov; 2002 Mar; 1(3):211-9. PubMed ID: 12120505 [TBL] [Abstract][Full Text] [Related]
8. NMR spectroscopy tools for structure-aided drug design. Homans SW Angew Chem Int Ed Engl; 2004 Jan; 43(3):290-300. PubMed ID: 14705081 [TBL] [Abstract][Full Text] [Related]
9. Nuclear magnetic resonance in target profiling and compound file enhancement. Sun C; Hajduk PJ Curr Opin Drug Discov Devel; 2006 Jul; 9(4):463-70. PubMed ID: 16889229 [TBL] [Abstract][Full Text] [Related]
10. Theory and applications of NMR-based screening in pharmaceutical research. Lepre CA; Moore JM; Peng JW Chem Rev; 2004 Aug; 104(8):3641-76. PubMed ID: 15303832 [No Abstract] [Full Text] [Related]
11. Epitope mapping of antibody-antigen complexes by nuclear magnetic resonance spectroscopy. Rosen O; Anglister J Methods Mol Biol; 2009; 524():37-57. PubMed ID: 19377935 [TBL] [Abstract][Full Text] [Related]
12. Epitope mapping of the phosphorylation motif of the HIV-1 protein Vpu bound to the selective monoclonal antibody using TRNOESY and STD NMR spectroscopy. Gharbi-Benarous J; Bertho G; Evrard-Todeschi N; Coadou G; Megy S; Delaunay T; Benarous R; Girault JP Biochemistry; 2004 Nov; 43(46):14555-65. PubMed ID: 15544326 [TBL] [Abstract][Full Text] [Related]
13. ID NMR Methods in ligand-receptor interactions. Zartler ER; Yan J; Mo H; Kline AD; Shapiro MJ Curr Top Med Chem; 2003; 3(1):25-37. PubMed ID: 12577989 [TBL] [Abstract][Full Text] [Related]
14. Epitope mapping and competitive binding of HSA drug site II ligands by NMR diffusion measurements. Lucas LH; Price KE; Larive CK J Am Chem Soc; 2004 Nov; 126(43):14258-66. PubMed ID: 15506793 [TBL] [Abstract][Full Text] [Related]
15. NMR in the acceleration of drug discovery. Sem DS; Pellecchia M Curr Opin Drug Discov Devel; 2001 Jul; 4(4):479-92. PubMed ID: 11727313 [TBL] [Abstract][Full Text] [Related]
16. Second-site NMR screening and linker design. Jahnke W; Flörsheimer A; Blommers MJ; Paris CG; Heim J; Nalin CM; Perez LB Curr Top Med Chem; 2003; 3(1):69-80. PubMed ID: 12570778 [TBL] [Abstract][Full Text] [Related]
17. Automation of biomolecular NMR screening. Ross A; Senn H Curr Top Med Chem; 2003; 3(1):55-67. PubMed ID: 12570777 [TBL] [Abstract][Full Text] [Related]
18. Informatics and modeling challenges in fragment-based drug discovery. Hubbard RE; Chen I; Davis B Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855 [TBL] [Abstract][Full Text] [Related]
19. Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: a heteronuclear NMR study. Grinstead JS; Schuman JT; Campbell AP Biochemistry; 2003 Dec; 42(48):14293-305. PubMed ID: 14640698 [TBL] [Abstract][Full Text] [Related]
20. Recent developments and applications of saturation transfer difference nuclear magnetic resonance (STD NMR) spectroscopy. Wagstaff JL; Taylor SL; Howard MJ Mol Biosyst; 2013 Apr; 9(4):571-7. PubMed ID: 23232937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]